Skip to main content

Molecular Quality Control Market Analysis and Forecast to 2028 By Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview

 


Molecular Quality Control Market Drivers

Expansion of business by key players is expected to boost the molecular quality control market growth. For instance, in July 2016, Bio-Rad Laboratories, Inc. announced its expansion into the molecular diagnostic testing market with the launch of its new quality control system Amplichek Quality Control. This quality control is used for molecular diagnostic testing of infectious diseases.

Furthermore, in April 2019, Bruker announced the expansion for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines. These products will be used for microbial identification, infection control, and molecular diagnostics of infectious diseases.

Moreover, increasing partnership activities are expected to drive the molecular quality control market growth. For instance, in February 2018, Randox Laboratories announced its strategic partnership with Qnostics to enhance the market potential of its Qnostics products.

Molecular Quality Control Market Restraints

Inaccurate genetic tests are expected to hinder growth of the molecular quality control market. For instance, in August 2017, Invitae Corporation identified a quality control issue with a hereditary cancer test, which provided false, negative results. This hereditary cancer test is carried out on those patient who have a rare genetic variant in the MSH2 gene which is associated with the Lynch syndrome.

Molecular Quality Control Market Regional Analysis

On the basis of region, the global molecular quality control market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global molecular quality control market, owing to increasing launches of new control panels by key players. For instance, in December 2018, Microbiologics, Inc. launched two new panels, Group A Streptococcus (GAS) and respiratory molecular assays, for quality control processes. These two panels include convenient features such as multiplexed pellets, swabs that mimic patient sample processing, and room temperature storage.

Furthermore, Asia Pacific is also projected to witness significant growth in the global molecular quality control market, owing to increasing partnership activities by key players. In June 2016, Thermo Fisher Scientific Inc., announced its partnership with West China Hospital of Sichuan University to enhance quality of pathological research and diagnosis and to accelerate development of precise pathological diagnosis.

Key players operating in the, global molecular quality control market include Seracare Life Sciences, Inc., Zeptometrix, Thermo Fisher Scientific, Abbott Laboratories, Maine Molecular Quality Controls, Inc., Quidel, Qnostics, Bio-Rad Laboratories, Roche Diagnostics, Microbiologics, Inc., and Theranostica.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more

Immuno-oncology: Combination Therapies and Emerging Targets

  The study of and creation of therapies that use the immune system of the body to combat cancer are known as immuno-oncology. Our immune system, which is made up of a complex web of organs, cells, and molecules, guards us against external invaders like bacteria, fungus, and viruses that might infect us. The immune system is capable of locating and eliminating foreign objects as well as attacking aberrant cells. The immune system has the best chance of specifically destroying tumours without harming healthy tissue and having long-term memory that can stop cancer from coming back. The development of tumours can be permanently prevented or managed by a mechanism known as immunosurveillance, according to research in immuno-oncology conducted over the past 30 years. Recognition of tumour antigens is what gives the immune response its tumour specificity. The most well-established therapeutic class of IO drugs to date, immune checkpoint inhibitors have demonstrated significant effic...
Post a Comment
Read more